Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

PURPOSE: The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC). PATIENTS AND METHODS: In this multicenter, two-stage, phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Reid, Alison H.M., Attard, Gerhardt, Danila, Daniel C., Oommen, Nikhil Babu, Olmos, David, Fong, Peter C., Molife, L. Rhoda, Hunt, Joanne, Messiou, Christina, Parker, Christopher, Dearnaley, David, Swennenhuis, Joost F., Terstappen, Leon W.M.M., Lee, Gloria, Kheoh, Thian, Molina, Arturo, Ryan, Charles J., Small, Eric, Scher, Howard I., de Bono, Johann S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2849770/
https://ncbi.nlm.nih.gov/pubmed/20159823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.6819
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados